-
The Artificial Intelligence Era in Health Economic Modeling
Sep 9, 2025, 16:22 PM -
Cost Analysis of Polatuzumab Vedotin in Combination With Rituximab Cyclophosphamide Doxorubicin and Prednisone in the Treatment of Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma in Portugal
Sep 9, 2025, 16:22 PM -
Scientific Outcome of ISPOR Conferences: An Analysis of 67,055 Abstracts Presented at 54 ISPOR Conferences Between 2002-2024
Sep 9, 2025, 16:22 PM -
Budget Impact of the VELYS™ Robotic-Assisted Solution Compared to Manual Procedure in Patients Undergoing Primary Total Knee Arthroplasty in Spain
Sep 9, 2025, 16:22 PM -
A Systematic Literature Review on Economic Evaluations and Cost-Effectiveness of Second-Line Treatment Options for Immune Thrombocytopenia
Sep 9, 2025, 16:22 PM -
Cost-Utility Analysis of Transcatheter Valve Replacement Using Valves With RESILIA Tissue for the Treatment of Aortic Stenosis in South Korea
Sep 9, 2025, 16:22 PM -
Humanistic and Financial Burden Experienced by Nonprofessional Care Partners of Patients With Mild Cognitive Impairment and Dementia Due to Alzheimer’s Disease: Results From a Real-World Survey in Spain
Sep 9, 2025, 16:22 PM -
Use of Multilevel Network Meta Regression (ML-NMR) Model in RET Mutation-Positive Medullary Thyroid Cancer (MTC)
Sep 9, 2025, 16:22 PM -
Navigating Uncertainty and Pragmatic Acceptance: Canadian Patient and Public Perspectives on Radiopharmaceutical Therapy in the Context of Whole Health
Sep 9, 2025, 16:22 PM -
Sex Differences in Autoimmune Multimorbidity Across 11 Autoimmune Disorders in the Real-World Setting in Germany
Sep 9, 2025, 16:22 PM -
Increased Functional Impairment Associated With Generalized Anxiety Disorder (GAD): Findings From a Systematic Literature Review
Sep 9, 2025, 16:22 PM -
The Greek Drug Price Negotiation Committee and Its Contribution in Optimizing the Management of EOPYY's Pharmaceutical Budget
Sep 9, 2025, 16:22 PM -
Competing Beyond the First Mover: How Late to Market Analogues Navigate Pricing and Access in Major Global Markets
Sep 9, 2025, 16:22 PM -
Conceptualizing an Economic Model Structure for Parkinson's Disease
Sep 9, 2025, 16:22 PM -
The Impact of Annual Price Revision Based on External Reference Pricing on Medicines Between 2012 and 2023 in Portugal
Sep 9, 2025, 16:22 PM -
Challenges at the Interface Between EUHTA (JCA) and National HTA in Germany (AMNOG): Expected Limitations to Synergy Effects and Implications for AMNOG Dossier Preparation
Sep 9, 2025, 16:22 PM -
Comparing HTA Outcomes and Rationale for Decision Making Between Countries With Mature vs. Newly Founded HTA Systems: Evidence From England, France, and Greece
Sep 9, 2025, 16:22 PM -
Leveraging Generative AI for Efficient Patient Safety Narrative Drafting: A Semaglutide Case Study
Sep 9, 2025, 16:22 PM -
Strengthening Routine Childhood Immunization Post-COVID: Global Strategies to Improve Coverage and Equity
Sep 9, 2025, 16:22 PM -
Use of a Nonparametric Bayesian Method to Model Health State Preferences: An Application to UAE EQ-5D-5L Valuations
Sep 9, 2025, 16:22 PM
